Lin, Yu-LinYu-LinLinJAU-YU LIAUSHAN-CHI YULI-HUI TSENGLIANG-IN LINJIN-TUNG LIANGBEEN-REN LINJI-SHIANG HUNGYIH-LEONG CHANGKUN-HUEI YEHANN-LII CHENG2022-04-202022-04-202013-061936-5233https://scholars.lib.ntu.edu.tw/handle/123456789/604890The identification of better regimens in currently available chemotherapeutic agents is crucial for treating patients with KRAS mutant metastatic colorectal cancer (mCRC). Records of mCRC patients who received first-line oxaliplatin-based or irinotecan-based regimens were reviewed retrospectively. Clinicopathologic features and treatment outcome of patients with first-line progression-free survival (PFS) and overall survival (OS) in association with KRAS mutation status were analyzed using the Cox proportional hazard model. Between 2007 and 2010, a total of 118 mCRC patients were enrolled. Among them, 67 were males and 51 were females. In patients who received first-line oxaliplatin-based regimens, the PFS was significantly longer in KRAS mutant patients (N = 32) than that in KRAS wild-type patients (N = 51). The median PFS was 8.5 months in KRAS mutant versus 5.8 months in KRAS wild-type patients (P = .008). In contrast, in patients who received first-line irinotecan-based regimens, the PFS was shorter in KRAS mutant patients (N = 15) than that in KRAS wild-type patients (N = 20). Median PFS was 3.9 months in KRAS mutant versus 6.0 months in KRAS wild-type patients (P = .23). Median OS between KRAS mutant and wild-type patients was not significantly different in both oxaliplatin-based and irinotecan-based regimens. In multivariate analyses, KRAS mutation remains an independent predictive factor for longer PFS in first-line oxaliplatin-based regimens. In conclusion, oxaliplatin-based chemotherapy in KRAS mutant mCRC might result in longer PFS than in KRAS wild-type mCRC.enDNA-DAMAGE RESPONSE; 1ST-LINE TREATMENT; CETUXIMAB; MUTATIONS; FLUOROURACIL; LEUCOVORIN[SDGs]SDG3journal article10.1593/tlo.13166237304172-s2.0-84878693356WOS:000328360000017https://scholars.lib.ntu.edu.tw/handle/123456789/473808